Oslo, 7 December 2016. PCI Biotech Holding ASA ("PCI Biotech" or the "Company") issues this notification on behalf of its chairman, Hans Peter Bøhn, and its CEO, Per Walday.
Hans Peter Bøhn is chairman of PCI Biotech and shall open the extraordinary general meeting of the Company on 8 December 2016. Mr. Bøhn holds 50,000 shares, representing 0.3 per cent of the share capital of PCI Biotech. By close of business on 6 December 2016 he had received powers of attorney to represent and vote for 5,569,610 additional shares. In total Mr. Bøhn will represent and vote for 37.7 per cent of the share capital. A major part of the powers of attorney are through the guarantee agreements entered into with the underwriting consortium and some of the powers of attorney may have voting instructions. The powers of attorney are only valid at this extraordinary general meeting.
Per Walday is CEO of PCI Biotech. Mr. Walday holds 44,019 shares, representing 0.3 per cent of the share capital of PCI Biotech. By close of business on 6 December 2016 he had received powers of attorney to represent and vote for 1,500,000 additional shares. In total Mr. Walday will represent and vote for 10.4% of the share capital. The powers of attorney are only valid at this extraordinary general meeting.
For further information, please contact:
Ronny Skuggedal, CFO, rs@pcibiotech.no, Mobile: +47 9400 5757
For more information visit: www.pcibiotech.com
Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo